Triplet therapy for advanced BCR::ABL1 positive myeloid leukaemias
Mené sur 20 patients atteints d'une leucémie myéloïde aiguë Ph+ ou d'une leucémie myéloïde en phase chronique et de stade avancé (âge médian : 43 ans ; durée médiane de suivi : 21,2 mois), cet essai de phase II évalue l'efficacité, du point de vue du taux de rémission complète ou incomplète, et la toxicité d'un traitement combinant décitabine, vénétoclax et ponatinib
Most patients presenting with chronic myeloid leukaemia are diagnosed with it in the chronic phase. With the widespread use of tyrosine kinase inhibitors such as imatinib, dasatinib, and nilotinib, patients with chronic phase-chronic myeloid leukaemia and optimal treatment responses can expect a normal life expectancy;1 a minority might even be able to successfully discontinue therapy.2 However, 2–3% of patients present with de novo blast phase-chronic myeloid leukaemia and a further 5% will progress to blast phase on treatment.3 Blast phase-chronic myeloid leukaemia is a poor prognosis myeloid, lymphoid, or bi-phenotypic acute leukaemia.4 Median overall survival from diagnosis of blast phase-chronic myeloid leukaemia is less than 12 months, and novel, effective treatment strategies are urgently being sought. The Lancet Haematology home. Opens in new tab Get full text